Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lilian W Adeojo

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmaceutics|August 29, 2024
A Physiologically-Based Pharmacokinetic Simulation to Evaluate Approaches to Mitigate Efavirenz-Induced Decrease in Levonorgestrel Exposure with a Contraceptive ImplantLilian W Adeojo, Rena C Patel, Nancy C Sambol
Journal of Clinical Pharmacology|July 16, 2021
Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity DisorderAzmi Nasser, Roberto Gomeni, Zhao Wang, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 15, 2021
Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree<sup>TM</sup>) in Healthy Adult SubjectsZhao Wang, Alisa R Kosheleff, Lilian W Adeojo, et al.
Clinical Therapeutics|March 14, 2024
Advanced Model-based Approach to Evaluate Human Plasma, Cerebrospinal Fluid, and Neuronal mTORC1 Activation Biomarkers After NV-5138 Administration in Healthy VolunteersAzmi Nasser, J Randall Owen, Roberto Gomeni, et al.
Clinical Pharmacology in Drug Development|May 4, 2021
Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy AdultsZhao Wang, Alisa R Kosheleff, Lilian W Adeojo, et al.
The Journal of Infectious Diseases|November 27, 2020
A Novel Encochleated Formulation Improves Atovaquone Activity in a Murine Model of Pneumocystis PneumoniaMelanie T Cushion, Parag Kumar, Ruying Lu, et al.
The International Journal of Neuropsychopharmacology|April 3, 2020
A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant DepressionLawrence T Park, Bashkim Kadriu, Todd D Gould, et al.
Annals of the Rheumatic Diseases|August 27, 2020
Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositisHanna Kim, Samantha Dill, Michelle O'Brien, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmaceutics|August 29, 2024
A Physiologically-Based Pharmacokinetic Simulation to Evaluate Approaches to Mitigate Efavirenz-Induced Decrease in Levonorgestrel Exposure with a Contraceptive ImplantLilian W Adeojo, Rena C Patel, Nancy C Sambol
Journal of Clinical Pharmacology|July 16, 2021
Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity DisorderAzmi Nasser, Roberto Gomeni, Zhao Wang, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 15, 2021
Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree<sup>TM</sup>) in Healthy Adult SubjectsZhao Wang, Alisa R Kosheleff, Lilian W Adeojo, et al.
Clinical Therapeutics|March 14, 2024
Advanced Model-based Approach to Evaluate Human Plasma, Cerebrospinal Fluid, and Neuronal mTORC1 Activation Biomarkers After NV-5138 Administration in Healthy VolunteersAzmi Nasser, J Randall Owen, Roberto Gomeni, et al.
Clinical Pharmacology in Drug Development|May 4, 2021
Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy AdultsZhao Wang, Alisa R Kosheleff, Lilian W Adeojo, et al.
The Journal of Infectious Diseases|November 27, 2020
A Novel Encochleated Formulation Improves Atovaquone Activity in a Murine Model of Pneumocystis PneumoniaMelanie T Cushion, Parag Kumar, Ruying Lu, et al.
The International Journal of Neuropsychopharmacology|April 3, 2020
A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant DepressionLawrence T Park, Bashkim Kadriu, Todd D Gould, et al.
Annals of the Rheumatic Diseases|August 27, 2020
Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositisHanna Kim, Samantha Dill, Michelle O'Brien, et al.
Pageof 1